Furthermore, the potential applications of SGLT-2 inhibitors in other kidney disease subtypes, such as IgA nephropathy, ADPKD, FSGS, and lupus nephritis, further broaden their clinical applications. This evidence concerns the gene SLC5A2 and IgA glomerulonephritis.